New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
08:17 EDTCELGAcceleron Pharma and Celgene initiate phase 2 study of ACE-536
Acceleron Pharma announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes, or MDS. MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia. Acceleron is developing ACE-536 in a global collaboration with Celgene. Acceleron earned a $10M milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200M for the ACE-536 program.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
13:21 EDTCELGAlphabet, Celgene, others could rise 20% over next year, Barron's says
Subscribe for More Information
November 20, 2015
10:52 EDTCELGFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 17, 2015
08:22 EDTCELGSignificant Celgene overhang removed, says JMP Securities
Subscribe for More Information
November 16, 2015
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use